This invention relates to a new crystalline form of Pridopidine, a drug substance currently in development for the treatment of Huntingtons disease. More specifically the invention provides polymorphic Form II of the Pridopidine hydrochloride salt, a process for the preparation of this polymorphic form, pharmaceutical compositions comprising polymorphic Form II, and methods of uses of this polymorphic form.